Dr. Anna Dieckmann and Dr. Lorenz Maier
Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.
Search
Learning and development
We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Employees join #stayhomeandfoster movement
Employees join #stayhomeandfoster movement
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
Ridgefield Research and Innovation
Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
Understand the burden of serious mental illness
Ethics and Compliance
Ethics and Compliance
Health disparities in Black and African Americans
Addressing social determinants of health in cardio-kidney-metabolic care
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women
FDA approved treatment option for adults with CKD
The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
Heart Failure
Heart Failure
How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health
Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Partnering for Innovation in Animal Health
Video with Erik Haaksma and Megan Grether describing how partnering is an essential component of innovation at Boehringer Ingelheim Animal Health.
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Working Together in Animal Health
Working Together in Animal Health
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
The Core of our Leitbild
Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.
Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim